ADMA BIOLOGICS, INC.

On July 10, 2026, plaintiff Lisa Mazzarino filed a putative securities class action lawsuit against the Company, Adam Grossman, our director, President and Chief Executive Officer, Jerrold Grossman, our Vice Chairman of the Board, and Brad Tade, our former Chief Financial Officer and Treasurer, in the United States District Court for the District of New Jersey. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The action seeks monetary damages in an unspecified amount. The litigation remains at a preliminary stage. We believe that the claims asserted in the lawsuit are without merit and intend to vigorously defend against the action. At this time, we are unable to predict the outcome of the litigation or reasonably estimate the amount or range of any potential loss, if any, that may result from the matter.

Item 1A.